#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Vulval cancer Mantle cell lymphoma Osteosarcoma metastatic Glioblastoma multiforme Congenital myopathy Short stature Ataxia telangiectasia Wolfram syndrome Anal fistula Prostate cancer Germ cell cancer Bronchiolitis Myasthenia gravis Ocular myasthenia Brain abscess More trials…

    Learn about Rare Diseases

    Myelodysplastic syndrome – Diagnostics Rhabdomyosarcoma Factor IX deficiency Soft tissue sarcoma – Basic Information Sarcoma – Treatment Testicular leiomyosarcoma – Basic Information Propionic acidaemia – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Diagnostics Factor IX deficiency – Trials in Disease Anaplastic thyroid cancer – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ribonucleic Acid K10 Dexpanthenol Sasanlimab Candesartan Tipiracil Corylus Avellana L. Budesonide Tyrosine Etoricoxib TEDUGLUTIDE Bms-986449-03 Acalabrutinib Autologous Chondrocytes GSKVX000000030918 Nms-03592088 99MTC-EUK-(SO3)CY5-MAS3 Paliperidone Gedatolisib Deoxyribonucleic Acid Sumatriptan Succinate More therapies…

    Learn about Your Condition

    Adrenal insufficiency Factor IX deficiency Endometrial cancer stage III Kaposi's sarcoma Nephroblastoma Graves' disease Osteotomy Liposarcoma recurrent Benign renal neoplasm Renal injury Malignant glioma Myxofibrosarcoma Autoimmune haemolytic anaemia Bladder cancer recurrent Peritoneal abscess More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Acute myeloid leukaemia recurrent

  • Phase 1/2 Study of LB-208 in Adults with Relapsed or Refractory Acute Myeloid Leukaemia and High‑Risk Myelodysplastic Syndrome

    Recruiting

    1 1 1
    Spain

  • A study testing AZD3632 alone or with other anticancer drugs in adults with acute leukemia or myelodysplastic syndromes with HOX gene overexpression

    Recruiting

    2 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia recurrent
    • Acute myeloid leukaemia recurrent
    • Acute myeloid leukaemia refractory
    Investigated Drugs:
    • AZD3632
    Denmark Germany Italy

  • Study on the Safety of Eganelisib Alone and with Cytarabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia recurrent
    • Acute myeloid leukaemia refractory
    Investigated Drugs:
    • EGANELISIB
    • Cytarabine
    Spain

  • Study on the Safety and Effectiveness of Eltanexor for Patients with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

    Recruiting

    2 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia recurrent
    • Acute myeloid leukaemia refractory
    Investigated Drugs:
    • ELTANEXOR
    Italy

  • Study on the Safety of CD19 CAR-T Cells, Cyclophosphamide, and Fludarabine in Adults with Refractory or Relapsed Acute Myeloid Leukemia Expressing CD19

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
    • Fludarabine Phosphate
    • Cyclophosphamide
    France

  • Study on CCTx-001, Cyclophosphamide Monohydrate, and Fludarabine Phosphate for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia recurrent
    • Acute myeloid leukaemia refractory
    Investigated Drugs:
    • Cctx-001
    • Fludarabine Phosphate
    • Cyclophosphamide Monohydrate
    France Germany Spain Sweden
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!